Loading...
Complicated skin and soft-tissue infections caused by gram-positive bacteria are on the rise worldwide. Because of the increasing role played by resistant pathogens, particularly methicillin-resistant Staphylococcus aureus (MRSA), physicians often must resort to antibiotics previously considered “second-line.” Ceftobiprole, an investigational pyrrolidinone cephalosporin, has good activity against major gram-negative and gram-positive bacteria, including MRSA, and therefore seems well suited for treating skin infections.
Investigators recently reported the results of an industry-sponsored, double-blind, multinational, phase III trial comparing ceftobiprole (500 mg) with vancomycin (1000 mg), both administered intravenously twice daily, in pat…